精选理由
前a16z生物科技负责人Vijay Pande分享为何从40亿基金转向小规模投资，谈AI如何改变医学研究。
Vijay Pande离开a16z管理的40亿美元生物科技实践后创立了规模更小的AI原生VZVC。他认为生物学正从'发现'科学转向'工程'科学。临床试验仍然极其昂贵，开放共享数据集而非封闭数据集将真正推动AI改变医学。
原文 · techcrunch
“We’re not doing 30 bets a year”: Vijay Pande on betting small after running $4 billion at a16z
Vijay Pande — who left a16z's roughly $4 billion biotech practice last year to start the much smaller, AI-native VZVC — talks about why biology is finally shifting from a "discovery" science to an "engineering" one, why clinical trials are still brutally expensive, and why he thinks open, shared datasets (not walled-off ones) are what will actually let AI transform medicine.